14 October 2022: Articles
Case Report: Successful Reversal of Residual Block with Sugammadex in a Patient Not Known to Have Myasthenia Gravis
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction , Clinical situation which can not be reproduced for ethical reasons
Ko-Ching Kou E , Chih-Shung Wong * , Tzong-Jeng Wu **DOI: 10.12659/AJCR.937128
Am J Case Rep 2022; 23:e937128
Table 1. The timeline of reverse agent administration in the emergence phase. Reverse agent dosage was 0.2 mg of glycopyrrolate for every 1 mg of neostigmine.
| Timeline | Reversal agent (dose) | Train-of-four ratio |
|---|---|---|
| 0 min | Neostigmine 3 mg | 16% |
| 15 min | Neostigmine 2 mg | 25% |
| 30 min | Neostigmine 1 mg | 25% |
| 40 min | Sugammadex 200 mg | 105% |